This study is to evaluate the safety and efficacy of a newly developed investigational formulation of Botulilium Neurotoxin, NT 201, as compared with placebo in participants with blepharospasm.
Patients who have a diagnosis of bilateral blepharospasm and are currently treated with a stable regimen of BOTOX® may qualify.
Though we are no longer enrolling for this study, please contact Jamie Walski, Clinical Research Coordinator, at (612) 625-4130 with any questions about this or any other study.
Return to: Medical School : Academic Health Center : myU : U of M Home
